Lebrikizumab: A Novel Interlukin 13 Monoclonal Antibody

Abstract

The prevalence of AD in adolescents is estimated at approximately 15% worldwide, with up to 50% suffering from moderate-to-severe disease. The recent treatment approaches to atopic dermatitis are novel mono clonal antibody lebrikizumab. A Lebrikizumab is a novel, high affinity, monoclonal antibody that selectively targets interleukin -13 and prevents formation of the interleukin -13Rα1/ interleukin -4Rα heterodimer receptor signaling complex. Lebrikizumab does not prevent interleukin -13 binding to the interleukin -13Rα2 decoy receptor, which is thought to be involved in endogenous regulation of interleukin-13. Interleukin -13 is the primary upregulated cytokine in atopic dermatitis skin and is the pathogenic mediator driving atopic dermatitis pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies that target interleukin-13. Lebrikizumab is a potent, neutralizing high-affinity antibody with a slow disassociation rate from interleukin-13. Additionally, lebrikizumab does not interfere with interleukin-13 clearance.